explore -WSS

explore

author：focus 2025-10-01 01:50:44 - browse：85

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： How digital tools helped lower hypertension in marginalized patients

focus

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

Readout Newsletter: Bluebird, CVS, Contineum

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Methadone treatment changes are coming. Do they go far enough?

To avoid data mishandling cases, universities eye AI and other tools

Why did Pfizer dish out millions for a Super Bowl ad?

leisure time

explore

focus

Hollywood unions extend contract negotiations for actors

Key House Republican on health care plans exit from Congress

After affirmative action ruling, medical educators look to 'holistic review'

Positive childhood experiences can help future health

In Memoriam: Notable people who died in 2023

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Supreme Court strikes down use of affirmative action

Neuroscience’s long legacy of racism

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

BioAge raises $170M for combination therapy with Zepbound

leisure time

To avoid data mishandling cases, universities eye AI and other tools

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Medicare threatens to cut off funding for HCA's Mission hospital

Biden report: The neurospychology of memory and aging

App could help diagnose ear infections more accurately — and at home

Virtual Event: March of the Biosimilars

hotspot

focus

leisure time

focus